NCT01695447

Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy

Randomised Controlled Trail of Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy After Pancreaticoduodenectomy

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: TingBo Liang · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether duct-to-mucosa is better than invagination in pancreaticojejunostomy after pancreaticoduodenectomy. This single-centre, open, randomized controlled trail is conducted following ISGPF criteria for pancreatic fistula (PF). The duration of the study is supposed to start from Jan 5th 2012 and last to Dec 2014, until 100 or more cases are accessible. Patients diagnosed with pancreatic cancer, peri-ampullar carcinoma or other benign or malignant diseases which need to operate pancreaticoduodenectomy will be included. Main outcomes are pancreatic fistula rate, mortality, morbidity, reoperation and hospital stay. The investigators assumption that duct-to-mucosa is better than invagination.

Conditions

• Pancreatic Neoplasms
• Biliary Tract Neoplasms

Interventions

Type	Name	Description
PROCEDURE	duct-to-mucosa
PROCEDURE	invagination
DEVICE	Internal stent	Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.

Timeline

• Start date: 2012-01-01
• Primary completion: 2017-12-01
• Completion: 2017-12-01
• First posted: 2012-09-28
• Last updated: 2017-01-26

Locations

1 site across 1 country: China